Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
Rhea-AI Summary
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, has announced its participation in the Capital Event Management Conference. The event will take place at the JW Marriott Miami in Aventura, Florida from November 22-24, 2024. The company, which develops innovative solutions for patients with neurological and mental disorders, is offering one-on-one investor meetings during the conference. Interested parties can schedule meetings through CEM representatives or by contacting KCSA Strategic Communications.
Positive
- None.
Negative
- None.
News Market Reaction – AIFF
In the trading session that priced this news, AIFF gained 0.66%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024.
To schedule a one-on-one investor meeting with management, please contact your representatives at CEM or email KCSA Strategic Communications at Firefly@KCSA.com.
About CEM
CEM curates exclusive live events and virtual meetings where issuers and investors have unique opportunities to connect 1:1 and build lasting relationships. Since 2011 CEM has provided issuers a forum to raise capital, gain market support, save time & money, and build relationships with leading North American small cap investors.
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Investor Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
